Matchpoint Therapeutics raises $150 million Series B to move oral T-cell modulator MPT-062 toward clinical trials

Matchpoint Therapeutics announced the closing of a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures and several existing backers.

The capital will be directed toward advancing the company’s lead oral T cell modulator, MPT-062, into human trials for autoimmune and inflammatory diseases, with clinical development slated to begin next year.

MPT-062 is positioned as a first-in-class, orally administered therapy that modulates T cells. It is being developed using Matchpoint’s Advanced Covalent Exploration platform, which applies machine‑learning models to design small‑molecule drugs for traditionally hard‑to‑target proteins.

Matchpoint already benefits from a $1 billion agreement with Novartis and ongoing support from Sanofi’s venture arm, underscoring strong industry confidence in its technology.